MA52812A - Inhibiteurs de sarm1 - Google Patents
Inhibiteurs de sarm1Info
- Publication number
- MA52812A MA52812A MA052812A MA52812A MA52812A MA 52812 A MA52812 A MA 52812A MA 052812 A MA052812 A MA 052812A MA 52812 A MA52812 A MA 52812A MA 52812 A MA52812 A MA 52812A
- Authority
- MA
- Morocco
- Prior art keywords
- sarm1 inhibitors
- sarm1
- inhibitors
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D275/00—Heterocyclic compounds containing 1,2-thiazole or hydrogenated 1,2-thiazole rings
- C07D275/02—Heterocyclic compounds containing 1,2-thiazole or hydrogenated 1,2-thiazole rings not condensed with other rings
- C07D275/03—Heterocyclic compounds containing 1,2-thiazole or hydrogenated 1,2-thiazole rings not condensed with other rings with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D453/00—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids
- C07D453/06—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids containing isoquinuclidine ring systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/08—Bridged systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic Table
- C07F5/02—Boron compounds
- C07F5/022—Boron compounds without C-boron linkages
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Toxicology (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862682054P | 2018-06-07 | 2018-06-07 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MA52812A true MA52812A (fr) | 2021-04-14 |
Family
ID=68770700
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA052812A MA52812A (fr) | 2018-06-07 | 2019-06-06 | Inhibiteurs de sarm1 |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US12624026B2 (fr) |
| EP (1) | EP3801503A4 (fr) |
| JP (1) | JP7481329B2 (fr) |
| CN (2) | CN120398784A (fr) |
| CA (1) | CA3108669A1 (fr) |
| MA (1) | MA52812A (fr) |
| WO (1) | WO2019236890A1 (fr) |
Families Citing this family (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US12448374B2 (en) | 2018-06-07 | 2025-10-21 | Disarm Therapeutics, Inc. | Inhibitors of SARM1 |
| MA52813A (fr) | 2018-06-07 | 2021-04-14 | Disarm Therapeutics Inc | Inhibiteurs de sarm1 |
| CN112955150A (zh) * | 2018-10-19 | 2021-06-11 | 达萨玛治疗公司 | 与nad+或nad+前体组合的sarm1抑制剂 |
| CN113164508B (zh) | 2018-12-19 | 2025-07-08 | 达萨玛治疗公司 | 与神经保护剂组合的sarm1抑制剂 |
| US12624025B2 (en) | 2019-06-06 | 2026-05-12 | Disarm Therapeutics, Inc. | Inhibitors of SARM1 |
| WO2020252229A2 (fr) | 2019-06-14 | 2020-12-17 | Disarm Therapeutics, Inc. | Inhibiteurs de sarm1 |
| US12441719B2 (en) | 2019-09-12 | 2025-10-14 | Disarm Therapeutics, Inc. | Inhibitors of SARM1 |
| AU2020391206A1 (en) * | 2019-11-26 | 2022-05-19 | Disarm Therapeutics, Inc. | Methods and compositions for neuroprotection |
| EP4083037A4 (fr) * | 2019-12-26 | 2024-01-24 | Yonsei University, University-Industry Foundation(UIF). | Dérivé de pyrrolidine et composition pharmaceutique de prévention ou de traitement de maladies associées à la protéine bêta-amyloïde ou tau contenant ce dernier |
| MX2022008395A (es) * | 2020-01-07 | 2022-09-26 | Disarm Therapeutics Inc | Inhibidores de sarm1. |
| WO2021207302A1 (fr) | 2020-04-09 | 2021-10-14 | Disarm Therapeutics, Inc. | Dérivés d'indazole utiles en tant qu'inhibiteurs de sarm1 |
| EP4132928B1 (fr) | 2020-04-09 | 2025-12-24 | Disarm Therapeutics, Inc. | Dérivés de pyrazole condensés comme inhibiteurs de sarm1 |
| EP4192828A1 (fr) | 2020-08-04 | 2023-06-14 | Nura Bio, Inc. | Dérivés de pyridine substitués utiles comme inhibiteurs de sarm1 |
| TWI904906B (zh) * | 2020-08-24 | 2025-11-11 | 美商達薩瑪治療公司 | Sarm1之抑制劑 |
| US11945796B2 (en) | 2020-09-16 | 2024-04-02 | Nura Bio, Inc. | Substituted pyridine derivatives as SARM1 inhibitors |
| CN114470215A (zh) * | 2020-11-12 | 2022-05-13 | 北京科辉智药生物科技有限责任公司 | Sarm1酶活性抑制剂及其在神经退行性疾病中的应用 |
| CN116568678B (zh) * | 2020-12-08 | 2025-07-18 | 达萨玛治疗公司 | Sarm1的苯并吡唑抑制剂 |
| TW202313009A (zh) | 2021-07-28 | 2023-04-01 | 美商努拉生物科技公司 | 作為sarm1抑制劑之經取代的吡啶衍生物 |
| CN118946553A (zh) * | 2022-04-08 | 2024-11-12 | 深圳众格生物科技有限公司 | Sarm1抑制剂化合物、包含其的药物组合物及其制备方法和用途 |
Family Cites Families (32)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ZA847926B (en) | 1983-10-17 | 1986-05-28 | Lilly Co Eli | 3-bicyclicpyridinium-methyl cephalosporins |
| EP0187456A1 (fr) | 1984-11-29 | 1986-07-16 | Ici Pharma | Dérivés de céphalosporine |
| UA60365C2 (uk) | 1998-06-04 | 2003-10-15 | Пфайзер Продактс Інк. | Похідні ізотіазолу, спосіб їх одержання, фармацевтична композиція та спосіб лікування гіперпроліферативного захворювання у ссавця |
| CA2707827A1 (fr) | 2001-04-11 | 2002-10-24 | Senju Pharmaceutical Co., Ltd. | Agents servant a ameliorer la fonction visuelle contenant des inhibiteurs de la rho kinase |
| US6989451B2 (en) | 2002-06-04 | 2006-01-24 | Valeant Research & Development | Heterocyclic compounds and uses thereof |
| US6727241B2 (en) * | 2002-06-12 | 2004-04-27 | Chemocentryx | Anti-inflammatory compositions and methods of use |
| JP2006516603A (ja) | 2003-01-27 | 2006-07-06 | ファイザー・プロダクツ・インク | イソチアゾール誘導体 |
| WO2005081997A2 (fr) | 2004-02-20 | 2005-09-09 | The Scripps Research Institute | Inhibiteurs des proteine kinases a base d'isothiazole |
| US7429667B2 (en) | 2005-01-20 | 2008-09-30 | Ardea Biosciences, Inc. | Phenylamino isothiazole carboxamidines as MEK inhibitors |
| US20060217390A1 (en) * | 2005-02-24 | 2006-09-28 | Esmir Gunic | Cycloalkl, aryl and heteroaryl amino isothiazoles for the treatment of Hepatitis C virus |
| US7557103B2 (en) | 2005-04-05 | 2009-07-07 | Eli Lilly And Company | Imidazopyridazine compounds |
| WO2006133417A1 (fr) * | 2005-06-07 | 2006-12-14 | Valeant Pharmaceuticals International | Phenylamino isothiazole carboxamidines comme inhibiteurs de mek |
| WO2008118626A2 (fr) | 2007-03-08 | 2008-10-02 | Burnham Institute For Medical Research | Inhibiteurs de jnk et procédés pour identifier des inhibiteurs de jnk |
| EP2152079A4 (fr) | 2007-06-04 | 2011-03-09 | Avila Therapeutics Inc | Composés hétérocycliques et utilisations de ceux-ci |
| WO2008157802A1 (fr) | 2007-06-21 | 2008-12-24 | Valeant Pharmaceuticals International | Dérivés 3-hydroxyisothiazole-4-carboxamidine comme inhibiteurs de la chk2 |
| WO2009041567A1 (fr) | 2007-09-27 | 2009-04-02 | Banyu Pharmaceutical Co., Ltd. | Dérivè de diaryl kétimine à activité antagoniste sur le récepteur de l'hormone de concentration de la mélanine |
| JP5576370B2 (ja) | 2008-08-06 | 2014-08-20 | ファイザー・インク | Ｃｈｋ−１阻害剤としての６置換２−ヘテロシクリルアミノピラジン化合物 |
| BR112012003284A8 (pt) | 2009-08-11 | 2016-05-17 | Allergan Inc | isotiozóis para tratar condições dos olhos |
| JP2013519681A (ja) | 2010-02-11 | 2013-05-30 | オーエスアイ・ファーマシューティカルズ，エルエルシー | ７−アミノフロピリジン誘導体 |
| DE102011009961A1 (de) | 2011-02-01 | 2012-08-02 | Merck Patent Gmbh | 7-Azaindolderivate |
| US9249087B2 (en) | 2011-02-01 | 2016-02-02 | The Board Of Trustees Of The University Of Illinois | HDAC inhibitors and therapeutic methods using the same |
| WO2012178022A2 (fr) | 2011-06-24 | 2012-12-27 | University Of Massachusetts | Applications thérapeutiques ciblant sarm1 |
| GB201310460D0 (en) | 2013-06-12 | 2013-07-24 | Lytix Biopharma As | Compounds |
| EP3481391A4 (fr) | 2016-07-11 | 2020-03-11 | Lifesci Pharmaceuticals, Inc. | Composés inhibiteurs thérapeutiques |
| WO2018035204A1 (fr) | 2016-08-16 | 2018-02-22 | Henry Ford Health System | Compositions pour le traitement de la douleur neuropathique et la sensibilisation des tumeurs aux chimiothérapies |
| WO2018057989A1 (fr) | 2016-09-24 | 2018-03-29 | Washington University | Inhibiteurs de l'activité sarm1 nadase et utilisations de ceux-ci |
| CN115448916B (zh) | 2016-10-14 | 2026-04-28 | 武田药品工业株式会社 | Tyk2抑制剂及其用途 |
| IL251949A0 (en) | 2017-04-26 | 2017-07-31 | Medical Res Infrastructure & Health Services Fund Tel Aviv Medical Ct | Small organic molecules for use in the treatment of neuro-inflammatory diseases |
| US12448374B2 (en) | 2018-06-07 | 2025-10-21 | Disarm Therapeutics, Inc. | Inhibitors of SARM1 |
| MA52813A (fr) | 2018-06-07 | 2021-04-14 | Disarm Therapeutics Inc | Inhibiteurs de sarm1 |
| CN113164508B (zh) * | 2018-12-19 | 2025-07-08 | 达萨玛治疗公司 | 与神经保护剂组合的sarm1抑制剂 |
| US12624025B2 (en) | 2019-06-06 | 2026-05-12 | Disarm Therapeutics, Inc. | Inhibitors of SARM1 |
-
2019
- 2019-06-06 EP EP19815890.9A patent/EP3801503A4/fr active Pending
- 2019-06-06 CA CA3108669A patent/CA3108669A1/fr active Pending
- 2019-06-06 US US16/972,670 patent/US12624026B2/en active Active
- 2019-06-06 CN CN202510537996.8A patent/CN120398784A/zh active Pending
- 2019-06-06 WO PCT/US2019/035846 patent/WO2019236890A1/fr not_active Ceased
- 2019-06-06 MA MA052812A patent/MA52812A/fr unknown
- 2019-06-06 JP JP2021518047A patent/JP7481329B2/ja active Active
- 2019-06-06 CN CN201980052440.2A patent/CN112867489A/zh active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| CN120398784A (zh) | 2025-08-01 |
| CN112867489A (zh) | 2021-05-28 |
| US20210261537A1 (en) | 2021-08-26 |
| EP3801503A4 (fr) | 2021-12-08 |
| EP3801503A1 (fr) | 2021-04-14 |
| CA3108669A1 (fr) | 2019-12-12 |
| WO2019236890A1 (fr) | 2019-12-12 |
| US12624026B2 (en) | 2026-05-12 |
| JP2021527126A (ja) | 2021-10-11 |
| JP7481329B2 (ja) | 2024-05-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL283639A (en) | Kif18a inhibitors | |
| MA54550A (fr) | Inhibiteurs de kif18a | |
| EP4007752C0 (fr) | Inhibiteurs de kif18a | |
| EP4007753C0 (fr) | Inhibiteurs de kif18a | |
| EP3801503A4 (fr) | Inhibiteurs de sarm1 | |
| EP4007756C0 (fr) | Inhibiteurs de kif18a | |
| IL269196A (en) | Novel inhibitors | |
| EP3843714A4 (fr) | Inhibiteurs de cd73 | |
| MA53287A (fr) | Inhibiteurs de prmt5 | |
| MA52813A (fr) | Inhibiteurs de sarm1 | |
| DK3740479T3 (da) | Dna-pk-hæmmere | |
| EP3788042A4 (fr) | Inhibiteurs de bcl-2 | |
| MA52413A (fr) | Inhibiteurs de cd73 | |
| EP3801499A4 (fr) | Inhibiteurs de sarm1 | |
| EP3541932A4 (fr) | Inhibiteurs de crispr-cas9 | |
| MA52635A (fr) | Inhibiteurs de magl | |
| EP3980011C0 (fr) | Inhibiteurs de sarm1 | |
| DK3571192T3 (da) | Jak1-selektive inhibitorer | |
| EP3856176A4 (fr) | Inhibiteurs de vap-1 | |
| EP3787635A4 (fr) | Inhibiteurs de cd73 | |
| EP3817736A4 (fr) | Inhibiteurs de pikfyve | |
| EP3773537A4 (fr) | Inhibiteurs de stat3 | |
| DK3630744T3 (da) | Pyrazol-magl-inhibitorer | |
| IL281514A (en) | O-glycoprotein-2-acetamido-2-deoxy-3-d-glucopyranosidase inhibitors | |
| EP3856194A4 (fr) | Inhibiteurs de vap-1 |